nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) has demonstrated clinical benefit in metastatic breast cancer (MBC) in a randomized phase III trial versus paclitaxel (CA012; N = 454) and in a randomized phase II trial versus docetaxel (CA024; N = 300). This retrospective analysis examines whe...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Shaughnessy, Joyce, Gradishar, William J., Bhar, Paul, Iglesias, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631516/
https://www.ncbi.nlm.nih.gov/pubmed/23563958
http://dx.doi.org/10.1007/s10549-013-2447-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631516/
https://www.ncbi.nlm.nih.gov/pubmed/23563958
http://dx.doi.org/10.1007/s10549-013-2447-8

Ejemplares similares